BOSTON--Celea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical ...
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, ...
Chief Executive Officer Marc Hertz and Chief Scientific Officer Vipin Kumar to present on translating immune biology and ...
New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, ...
Idiopathic Pulmonary Fibrosis is a disease in which various inflammatory and fibrotic signals interact, leading to excessive ...
AI models suggest IPF is a dysregulation of aging, not just accelerated aging, with unique gene expression patterns. Key pathways in IPF and aging include TGF-β signaling, oxidative stress, ...
CDER's acceptance of PROLIFIC's Letter of Intent (LOI) is an important early milestone that allows the consortium to move forward in the FDA's review toward potential qualification for use in drug ...
CAMBRIDGE, Mass., Sept. 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first ...
Editor's Note: Idiopathic pulmonary fibrosis (IPF) is a disease of unknown cause, affecting mostly older adults. Confined to the lungs, the disease causes lung tissue to become thick and scarred over ...
What is idiopathic pulmonary fibrosis (IPF)? Idiopathic pulmonary fibrosis (IPF) is a debilitating and fatal lung disease that affects approximately 3 million people worldwide. Despite the condition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results